International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

A. Palumbo, O. Sezer, R. Kyle, J. S. Miguel, R. Z. Orlowski, P. Moreau, R. Niesvizky, G. Morgan, R. Comenzo, P. Sonneveld, S. Kumar, R. Hajek, S. Giralt, S. Bringhen, K. C. Anderson, P. G. Richardson, M. Cavo, F. Davies, J. Blade, H. EinseleM. A. Dimopoulos, A. Spencer, A. Dispenzieri, T. Reiman, K. Shimizu, J. H. Lee, M. Attal, M. Boccadoro, M. Mateos, W. Chen, H. Ludwig, D. Joshua, J. Chim, V. Hungria, Ingemar Turesson, B. G. M. Durie, S. Lonial

Research output: Contribution to journalReview articlepeer-review

Abstract

In 2005, the first guidelines were published on the management of patients with multiple myeloma (MM). An expert panel reviewed the currently available literature as the basis for a set of revised and updated consensus guidelines for the diagnosis and management of patients with MM who are not eligible for autologous stem cell transplantation. Here we present recommendations on the diagnosis, treatment of newly diagnosed non-transplant-eligible patients and the management of complications occurring during induction therapy among these patients. These guidelines will aid the physician in daily clinical practice and will ensure optimal care for patients with MM. Leukemia (2009) 23, 1716-1730; doi: 10.1038/leu.2009.122; published online 4 June 2009
Original languageEnglish
Pages (from-to)1716-1730
JournalLeukemia
Volume23
Issue number10
DOIs
Publication statusPublished - 2009

Bibliographical note

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200)

Subject classification (UKÄ)

  • Cancer and Oncology

Free keywords

  • chemotherapy
  • treatment
  • myeloma
  • guidelines

Fingerprint

Dive into the research topics of 'International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation'. Together they form a unique fingerprint.

Cite this